Payer / HTA meeting · Dr. Rosa Garcia

03 Sept 2026 · In person · Dr. Rosa Garcia, Kyoto University Hospital · MSL James Whitfield · Lumeva

ReviewedVeeva CRMENG-0210—

Capture insight from this engagement

Location: Kyoto University Hospital
Therapeutic area: Neurology
Country: Japan
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Lumeva (lumevarin)

Topics discussed

Dosing in hepatic impairment
Real-world persistence
Drug interactions

Scientific content used

Chronic migraine scientific platform
LMV persistence data summary

Questions raised

No questions recorded.

Notes

Payer / HTA meeting with general neurologist at Kyoto University Hospital. Discussed dosing in hepatic impairment, real-world persistence, drug interactions.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 4
Depth of exchange: 4
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0210

Audit history (0)

All create, update and approval events for this record

No audit events in sample data